Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NKTX
SellSinkerNkarta, Inc. · Healthcare · United States · $198M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Nkarta, Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf, engineered natural killer (NK) cell therapies for cancer. Its proprietary NK cell platform aims to overcome limitations of other cell therapies by offering scalable, allogeneic treatments with broad applicability across various cancers. Nkarta is a pioneering biotechnology firm focused on advancing the next generation of cancer immunotherapy through innovative NK cell technology.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -2.62 | -2.61 | -2.40 | -1.60 | -1.41 | — | -1.59 | -1.71 | -1.75 | — |
| Shares | 33.0M | 48.9M | 49.2M | 70.6M | 71.1M | +115.6% | 71.6M | — | — | — |
| Debt | 12.5M | 82.9M | 88.3M | 80.3M | 76.4M | 57.4% | 73.5M | — | — | — |
| Equity | 251.0M | 372.2M | 273.3M | 408.0M | 312.3M | 5.6% | — | — | — | — |
| Op CF | -67.9M | -57.0M | -86.2M | -99.7M | -88.7M | — | -92.8M | — | — | — |
| Inv CF | 32.5M | -184.7M | 79.0M | -129.6M | 100.3M | — | — | — | — | — |
| Fin CF | 1.2M | 219.0M | 0.7M | 226.1M | 0.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NKTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NKTX | Nkarta, Inc.(you) | $198M | 22 | Sell |
| CDXS | Codexis, Inc. | $174M | 21 | Sell |
| IMUX | Immunic, Inc. | $210M | 26 | Sell |
| NRXP | NRx Pharmaceuticals, Inc. | $154M | 23 | Sell |
| CUE | Cue Biopharma, Inc. | $203M | 16 | Strong Sell |
| KRRO | Korro Bio, Inc. | $190M | 17 | Strong Sell |
| DTIL | Precision BioSciences, Inc. | $215M | 28 | Sell |
| KROS | Keros Therapeutics, Inc. | $219M | 16 | Strong Sell |
| IRD | Opus Genetics, Inc. | $307M | 22 | Sell |
| BDTX | Black Diamond Therapeutics, Inc. | $128M | 22 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%